Emma Anne Meagher

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Attending Physician, Hospital of the University of Pennsylvania, University of Pennsylvania Health System
Director, Patient Oriented Research Training Program , University of Pennsylvania School of Medicine
Associate Director, Cardiovascular Risk Intervention Program, University of Pennsylvania Health System
Executive Chair, Institutional Review Board, University of Pennsylvania School of Medicine
Director, Master of Science Degree program in Translational Research, University of Pennsylvania Perelman School of Medicine
Director, Translational Research Education, Institute of Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Associate Dean Medical School Admissions, University of Pennsylvania Perelman School of Medicine
Associate Vice Provost for Human Research, University of Pennsylvania
Associate Dean for Clinical Research, University of Pennsylvania Perelman School of Medicine
Department: Medicine

Contact information
ITMAT
8032 Maloney Building
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104-4283
Office: 215-662-2174
Fax: 215-614-0378
Education:
M.D. (Medicine)
Royal College of Surgeons in Ireland, 1987.
Permanent link
 

Description of Research Expertise

Dr. Meagher's research interests include mechanisms of vascular dysfunction in cardiovascular disease, alcohol induced liver disease and the role of antioxidant vitamin therapy in both primary and secondary prevention of disease. Dr. Meagher is also interested in the field of oxidant injury in atherosclerosis. Her clinical practice is in the area of cardiovascular risk modification with an emphasis on management of dyslipidemia, hypertension and women's cardiovascular health.

Description of Itmat Expertise

1. Evaluation of novel therapeutic approaches in hypertension and hyperlipidemia

2. Development and evaluation of educational approaches to translational reserach and preventing cardiovascular disease.

Selected Publications

Meagher, E., Ziolek, T., Singleton, MK, Davison, C., & Heagerty, D. : Training and Retaining MD and Other Scientist Members: A Symbiotic Partnership between IRBs and Academic Programs. Poster presented at the PRIM&R Annual Advancing Ethical Research Conference, Boston, MA. November 2013.

Meagher EA, Ziolek TS, Van den Broek J. : Ethics Support. Epidemiology: Principles and Practical Guidelines. Springer: 297-310 2013.

Cuchel M, Blom DJ, Averna MR, Meagher EA, du Toit Theron H, Sirtori CR, Niguarda O, Hegele RA, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Bloedon LT, Rader DJ: HoFH Lomitapide Study Investigators: Sustained LDL-C Lowering and Stable Hepatic Fat Levels in Patients with Homozygous Familial Hypercholesterolemia Treated with the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide: Results of an Ongoing Long-Term Extension Study. American Heart Association's 2013 Scientific Sessions, Dallas, TX 2013.

Meagher EA, Bastian RA: Training the next generation of translational scientists: the UPenn experience. Translational Science 2013, Clinical and Translational Science, 6: 103–164. 2013.

Blair, M., Eng, M., Singleton, M.K., Ziolek, T., & Meagher, E. : Incidental Pregnancy Follow-up and Data Collection: An Efficient Approach. Poster presented at the PRIM&R Annual Advancing Ethical Research Conference, San Diego, CA. December 2012.

Stanko, P., Ziolek, T., Heagerty, D., Hernberg, B., Fong, E., Singleton, MK, & Meagher, E. : Using IRB Metrics to Present and Evaluate Services Provided to the Research Community. Poster presented at the PRIM&R Annual Advancing Ethical Research Conference, San Diego, CA. December 2012.

Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ: A Phase 3 study of lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor, in patients with homozygous familial hypercholesterolemia. European Atherosclerosis Society. 80th Congress, 25 28 May 2012, Milan, Italy. Oral presentation. 2012.

Rader DJ, Meagher EA, Cuchel M, On behalf of the Phase 3 HoFH Lomitapide Study Investigators.: A Phase 3 study of the Microsomal Triglyceride Transfer Protein (MTP) Inhibitor Lomitapide in Patients with Homozygous Familial Hypercholesterolemia. National Lipid Association 2012 Scientific Sessions. 2012.

Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ : Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 380(11), 2012.

Holmes, J., Singleton, M.K., Schwarzhoff, A., Ziolek, T., Meagher, E., & Schreiner, M. : The Experience of a Cooperative Agreement at the Children’s Hospital of Philadelphia and the University of Pennsylvania. Poster presented at the PRIM&R Annual Conference, National Harbor, MD. December 2011.

back to top
Last updated: 03/06/2014
The Trustees of the University of Pennsylvania